POCI
BEARISH
$4.7
Live
Precision Optics Corporation, Inc. · NASDAQ
$3.55
52W Range
$6.04
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 17, 2026
Market cap
$51.36M
P/E
N/A
ROE
-73.6%
Profit margin
-28.3%
Debt/Equity
0.47
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
POCI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows impressive top-line revenue growth of 62.80%, this growth is not translating into profitability, as evidenced by a -28.33% profit margin and a catastrophic -73.56% ROE. Liquidity is tight with a Quick Ratio of 0.58, and the company has failed to beat earnings estimates in the last four quarters. The recent short-term price rally appears decoupled from the underlying financial deterioration.
Key Strengths
Strong YoY revenue growth of 62.80%
Strong Q/Q revenue growth of 62.76%
Relatively low Debt/Equity ratio of 0.47
Recent short-term price momentum (1W +17.8%)
Operating in the high-demand Healthcare sector
Key Risks
Critical Piotroski F-Score (1/9) indicating poor financial health
Deeply negative profitability (Profit Margin -28.33%, ROE -73.56%)
Poor liquidity position with a Quick Ratio of 0.58
Consistent earnings misses with an average surprise of -48.61%
Very low gross margins (9.70%) for the medical instruments industry
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
20
50
30
10
0
AI Verdict
High Risk / Speculative
Key drivers: Severe fundamental weakness (Piotroski 1/9), Negative earnings trajectory, High revenue growth vs. negative margins
Confidence
90%
Value
20/100
P/B 3.89, P/S 2.10, Graham Number N/A
Positives
No standout positives identified.
Watchpoints
- Price/Book of 3.89 is high for a company with negative ROE
- No positive earnings to support a P/E valuation
Future
50/100
Ref Revenue Growth 62.80% vs EPS Growth -333.3%
Positives
- Rapid revenue expansion (>60%)
Watchpoints
- Earnings growth is plummeting (-333.3% YoY)
- Inability to scale revenue into profit
Past
30/100
Ref 3Y Change -29%, Earnings Surprise -48.61%
Positives
- Recent 1-year price recovery (+17.5%)
Watchpoints
- 3-year price decline of 29%
- Consistent failure to meet analyst expectations
Health
10/100
Ref Piotroski F-Score 1/9, Quick Ratio 0.58
Positives
- Debt/Equity is below sector average
Watchpoints
- Piotroski F-Score 1/9 is critically low
- Quick Ratio 0.58 indicates liquidity risk
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- Negative earnings preclude dividend initiation
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.7
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for POCI and closest competitors.
Updated 2026-04-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
POCI
Precision Optics Corporation, Inc.
Primary
|
-7.8% | -29.0% | +17.5% | +13.0% | +13.2% | +17.8% |
|
PETS
PetMed Express, Inc.
Peer
|
-91.2% | -84.4% | -23.0% | -7.9% | -8.2% | +1.3% |
|
MGX
Metagenomi Therapeutics, Inc.
Peer
|
-86.4% | -86.4% | -7.9% | -50.9% | -4.1% | +2.9% |
|
HYFT
MindWalk Holdings Corp.
Peer
|
-91.3% | -62.5% | +166.8% | -40.9% | -16.4% | -6.1% |
|
NTRB
Nutriband Inc.
Peer
|
-28.9% | +17.2% | -16.9% | -45.8% | +7.4% | +4.1% |
POC
Precision Optics Corporation, Inc.
Primary
5Y
-7.8%
3Y
-29.0%
1Y
+17.5%
6M
+13.0%
1M
+13.2%
1W
+17.8%
PET
PetMed Express, Inc.
Peer
5Y
-91.2%
3Y
-84.4%
1Y
-23.0%
6M
-7.9%
1M
-8.2%
1W
+1.3%
MGX
Metagenomi Therapeutics, Inc.
Peer
5Y
-86.4%
3Y
-86.4%
1Y
-7.9%
6M
-50.9%
1M
-4.1%
1W
+2.9%
HYF
MindWalk Holdings Corp.
Peer
5Y
-91.3%
3Y
-62.5%
1Y
+166.8%
6M
-40.9%
1M
-16.4%
1W
-6.1%
NTR
Nutriband Inc.
Peer
5Y
-28.9%
3Y
+17.2%
1Y
-16.9%
6M
-45.8%
1M
+7.4%
1W
+4.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
3.89
P/S Ratio
2.1
EV/Revenue
1.63
EV/EBITDA
-6.15
Market Cap
$51.36M
Profitability
Profit margins and return metrics
Profit Margin
-28.33%
Operating Margin
-23.65%
Gross Margin
9.7%
ROE
-73.56%
ROA
-20.83%
Growth
Revenue and earnings growth rates
Revenue Growth
+62.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+62.76%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.47
Low debt
Current Ratio
1.05
Good
Quick Ratio
0.58
Poor
Cash/Share
$0.11
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
2.8%
Op. Margin
-23.6%
Net Margin
-24.2%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.45x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
138%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-14
$N/A
2001-08-21
$-2.34
-8.3% surprise
2001-05-09
$-1.98
-37.5% surprise
2001-02-07
$-1.44
-100.0% surprise
Healthcare Sector Comparison
Comparing POCI against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-73.56%
This Stock
vs
-101.52%
Sector Avg
-27.5%
(Below Avg)
Profit Margin
-28.33%
This Stock
vs
-12.47%
Sector Avg
+127.2%
(Superior)
Debt to Equity
0.47
This Stock
vs
3.4
Sector Avg
-86.1%
(Less Debt)
Revenue Growth
62.8%
This Stock
vs
124.21%
Sector Avg
-49.4%
(Slower)
Current Ratio
1.05
This Stock
vs
4.56
Sector Avg
-77.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
POCI
Precision Optics Corporation, Inc.
|
BEARISH | $51.36M | - | -73.6% | -28.3% | $4.7 | |
|
PETS
PetMed Express, Inc.
|
BEARISH | $50.08M | - | -100.6% | -34.7% | $2.34 | Compare |
|
MGX
Metagenomi Therapeutics, Inc.
|
BEARISH | $52.67M | - | -44.7% | -% | $1.4 | Compare |
|
HYFT
MindWalk Holdings Corp.
|
BEARISH | $49.98M | - | -58.8% | -43.6% | $1.07 | Compare |
|
NTRB
Nutriband Inc.
|
BEARISH | $49.67M | - | -136.1% | -% | $4.08 | Compare |
POCI
Precision Optics...
BEARISH
Mkt Cap
$51M
P/E
-
ROE
-73.6%
Price
$4.7
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | COLL WAYNE M | Chief Financial Officer | Stock Award | 1,568 | $6,248 |
| 2026-03-30 | COLL WAYNE M | Chief Financial Officer | Purchase | 20,833 | $74,999 |
| 2026-03-30 | FORKEY JOSEPH NORMAN | Chief Executive Officer | Purchase | 1,388 | $4,997 |
| 2026-03-30 | TRAUT JOSEPH | Chief Operating Officer | Purchase | 41,666 | $149,998 |
| 2026-03-12 | MICLOT ANDREW J | Director | Option Exercise | 20,000 | $28,800 |
| 2025-12-31 | COLL WAYNE M | Chief Financial Officer | Stock Award | 5,528 | $24,319 |
COLL WAYNE M
Chief Financial Officer
2026-03-31
1,568 shares
·
$6,248
COLL WAYNE M
Chief Financial Officer
2026-03-30
20,833 shares
·
$74,999
FORKEY JOSEPH NORMAN
Chief Executive Officer
2026-03-30
1,388 shares
·
$4,997
TRAUT JOSEPH
Chief Operating Officer
2026-03-30
41,666 shares
·
$149,998
MICLOT ANDREW J
Director
2026-03-12
20,000 shares
·
$28,800
COLL WAYNE M
Chief Financial Officer
2025-12-31
5,528 shares
·
$24,319
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
10-Q
DEF 14A
10-Q
8-K
10-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Past News Coverage
Recent headlines mentioning POCI from our newsroom.
Newest → oldest
No matching news yet.